Profile picture

Assistant Professor Peter Jirak

Salzburg university hospital, Salzburg (Austria)
Follow
Logo ESC

Contributor content

Dexamethasone improves cardiovascular outcomes in critically ill COVID-19, a real world scenario multicenter analysis
Presentation
Dexamethasone improves cardiovascular outcomes in critically ill COVID-19, a real world scenario multicenter analysis
Dexamethasone treatment attenuates pulmonary embolism rates in severe COVID-19 disease
Presentation
Dexamethasone treatment attenuates pulmonary embolism rates in severe COVID-19 disease
C - reactive protein is a promising indicator of  ventricular arrhythmias in pacemaker patients
Presentation
C - reactive protein is a promising indicator of ventricular arrhythmias in pacemaker patients
Higher incidence of stroke in severe COVID-19 is not associated with a higher burden of arrhythmias: Comparison to other types of severe pneumonia
Presentation
Higher incidence of stroke in severe COVID-19 is not associated with a higher burden of arrhythmias: Comparison to other types of severe pneumonia
Changes in micro-RNA secretion patterns following an anti-CD3 and ATG treatment regulate expression of adherens junctions in PBMCs
Presentation
Changes in micro-RNA secretion patterns following an anti-CD3 and ATG treatment regulate expression of adherens junctions in PBMCs
Analysis of novel cardiac markers sST2 and IL-33 in chronic heart failure with reduced ejection fraction
Presentation
Analysis of novel cardiac markers sST2 and IL-33 in chronic heart failure with reduced ejection fraction
Differences in the expression of the novel cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in HFpEF, ICM and DCM patients
Presentation
Differences in the expression of the novel cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in HFpEF, ICM and DCM patients
A comparative analysis of novel biomarkers in sepsis and cardiovascular disease
Presentation
A comparative analysis of novel biomarkers in sepsis and cardiovascular disease
A comparative analysis of the novel cardiac biomarkers sST2, GDF-15, Galectin-3, suPAR, H-FABP and Fetuin-A in heart failure, STEMI and NSTEMI patients
Presentation
A comparative analysis of the novel cardiac biomarkers sST2, GDF-15, Galectin-3, suPAR, H-FABP and Fetuin-A in heart failure, STEMI and NSTEMI patients
A comparative analysis of novel cardiac biomarkers (sST2, GDF-15, Galectin-3, suPAR, H-FABP and Fetuin-A) in patients with heart failure, STEMI and controls without cardiovascular disease
Presentation
A comparative analysis of novel cardiac biomarkers (sST2, GDF-15, Galectin-3, suPAR, H-FABP and Fetuin-A) in patients with heart failure, STEMI and controls without cardiovascular disease

ESC 365 is supported by